3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
20
Lung Neoplasms
9
Small Cell Lung Carcinoma
6
Neoplasms
5
Carcinoma, Hepatocellular
5
Carcinoma
4
Urinary Bladder Neoplasms
3
Pancreatic Neoplasms
3
Neoplasms by Site
3
Neoplasm Metastasis
3
Endometrial Neoplasms
3
Cholangiocarcinoma
3
Neoplasms by Histologic Type
2
Liver Neoplasms
2
Gallbladder Neoplasms
2
Bile Duct Neoplasms
2
Vaccinia
1
Triple Negative Breast Neoplasms
1
Thoracic Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Resectable Intrahepatic Cholangiocarcinoma
1
Renal Pelvis and Ureter Urothelial Carcinoma
1
Pathologic Complete Response
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Oropharyngeal Neoplasms
1
Non-Small Cell Lung Cancer Metastatic
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Interventions
Oxaliplatin
3
Leucovorin
3
Fluorouracil
3
Capecitabine
3
zolbetuximab
2
trastuzumab deruxtecan
2
pembrolizumab
2
Ramucirumab
2
Paclitaxel
2
repotrectinib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
durvalumab
1
darolutamide
1
aldesleukin
1
Vinorelbine
1
Radiosurgery
1
Radiation
1
Prednisone
1
Prednisolone
1
Positron-Emission Tomography
1
Pemetrexed
1
PF06821497
1
Nivolumab
1
Negative-Pressure Wound Therapy
1
Microscopy, Confocal
1
MORAb-202
1
Irinotecan
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
durvalumab
×
30 days
×
Clear all
NCT05063565
2026-06-01
ROWAN
Boston Scientific Corporation
Phase 2
Active not recruiting
100 enrolled